Ipsen Acquires German Biotech Memo Therapeutics in 200 Million Euro Deal
Ysios Capital, a leading European venture capital firm in life sciences, announced the divestment of Memo Therapeutics AG following its acquisition by global biopharmaceutical company Ipsen. The deal includes an initial payment of 200 million euros.